Literature DB >> 22218925

The "HER2-PI3K/Akt-FASN Axis" regulated malignant phenotype of colorectal cancer cells.

Nan Li1, Xiaodong Bu, Peng Wu, Pingping Wu, Peilin Huang.   

Abstract

Recent evidence suggests that HER2 (ErbB2; Her-2/neu) and the related PI3K/Akt signaling pathway substantially affect the malignant phenotype of colorectal cancer cells. Moreover, fatty acid synthase (FASN), which mediates de-novo fatty acid synthesis, is crucially important in the carcinogenesis process of a variety of cancers, including colorectal cancer. The purpose of this study was to investigate the malignant phenotype regulation of colorectal cancer cells via the "HER2-PI3K/Akt-FASN axis". Caco-2 cells with high expression of HER2 and FASN and high transfection efficiency were selected for functional characterization. The cells were transfected with either HER2-specific RNAi plasmid or negative control RNAi plasmid, followed by Q-RT-PCR and western blot assays to examine expression of HER2, PI3K, Akt, and FASN. MTT and colony-formation assays were used to assess proliferation. Migration was investigated by use of the transwell assay, and apoptosis and cell cycle were assayed by use of flow cytometry. Expression of HER2, PI3K, Akt, and FASN were downregulated when HER2 was silenced. Proliferation decreased after downregulation of HER2, which was consistent with increased apoptosis. Migration of HER2-silenced cells was also impaired. Loss of HER2 inhibits the activity of the "HER2-PI3K/Akt-FASN axis" of Caco-2 cells, and reduced activity of this axis alters the malignant behavior of Caco-2 cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22218925     DOI: 10.1007/s11745-011-3649-7

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  28 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Signal transduction and oncogenesis by ErbB/HER receptors.

Authors:  Mina D Marmor; Kochupurakkal Bose Skaria; Yosef Yarden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-01       Impact factor: 7.038

Review 3.  EGF-ERBB signalling: towards the systems level.

Authors:  Ami Citri; Yosef Yarden
Journal:  Nat Rev Mol Cell Biol       Date:  2006-07       Impact factor: 94.444

4.  Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas.

Authors:  I Porebska; A Harlozińska; T Bojarowski
Journal:  Tumour Biol       Date:  2000 Mar-Apr

Review 5.  Fatty acid synthase and cancer: new application of an old pathway.

Authors:  Francis P Kuhajda
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

6.  HER2 expression in breast cancer cells is downregulated upon active targeting by antibody-engineered multifunctional nanoparticles in mice.

Authors:  Fabio Corsi; Luisa Fiandra; Clara De Palma; Miriam Colombo; Serena Mazzucchelli; Paolo Verderio; Raffaele Allevi; Antonella Tosoni; Manuela Nebuloni; Emilio Clementi; Davide Prosperi
Journal:  ACS Nano       Date:  2011-08-01       Impact factor: 15.881

7.  Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation.

Authors:  Javier A Menendez; Inderjit Mehmi; Vishal A Verma; Poh K Teng; Ruth Lupu
Journal:  Mol Carcinog       Date:  2004-11       Impact factor: 4.784

8.  Diosgenin, a naturally occurring steroid, suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt, mTOR and JNK phosphorylation.

Authors:  Chun-Te Chiang; Tzong-Der Way; Shang-Jie Tsai; Jen-Kun Lin
Journal:  FEBS Lett       Date:  2007-11-20       Impact factor: 4.124

9.  Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.

Authors:  Toshiro Migita; Stacey Ruiz; Alessandro Fornari; Michelangelo Fiorentino; Carmen Priolo; Giorgia Zadra; Fumika Inazuka; Chiara Grisanzio; Emanuele Palescandolo; Eyoung Shin; Christopher Fiore; Wanling Xie; Andrew L Kung; Phillip G Febbo; Aravind Subramanian; Lorelei Mucci; Jing Ma; Sabina Signoretti; Meir Stampfer; William C Hahn; Stephen Finn; Massimo Loda
Journal:  J Natl Cancer Inst       Date:  2009-03-24       Impact factor: 13.506

10.  Pharmacological inhibitor of fatty acid synthase suppresses growth and invasiveness of renal cancer cells.

Authors:  Akio Horiguchi; Tomohiko Asano; Takako Asano; Keiichi Ito; Makoto Sumitomo; Masamichi Hayakawa
Journal:  J Urol       Date:  2008-06-13       Impact factor: 7.450

View more
  7 in total

1.  An integrated approach to identify causal network modules of complex diseases with application to colorectal cancer.

Authors:  Zhenshu Wen; Zhi-Ping Liu; Zhengrong Liu; Yan Zhang; Luonan Chen
Journal:  J Am Med Inform Assoc       Date:  2012-09-11       Impact factor: 4.497

Review 2.  Research progress on FASN and MGLL in the regulation of abnormal lipid metabolism and the relationship between tumor invasion and metastasis.

Authors:  Jingyue Zhang; Yawen Song; Qianqian Shi; Li Fu
Journal:  Front Med       Date:  2021-05-11       Impact factor: 4.592

3.  MAPK/P53-mediated FASN expression in bone tumors.

Authors:  Ye Jiang; Xiaofan Yin; Liang Wu; Qiang Qin; Jun Xu
Journal:  Oncol Lett       Date:  2017-04-10       Impact factor: 2.967

Review 4.  Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer.

Authors:  Ke-Tao Jin; Bo Chen; Yu-Yao Liu; H Uan-Rong Lan; Jie-Ping Yan
Journal:  Cancer Cell Int       Date:  2021-02-01       Impact factor: 5.722

5.  An IGF-1R-mTORC1-SRPK2 signaling Axis contributes to FASN regulation in breast cancer.

Authors:  Bryan McClellan; Paul Gries; Brittany Harlow; Stefano Tiziani; Christopher Jolly; Linda deGraffenried
Journal:  BMC Cancer       Date:  2022-09-12       Impact factor: 4.638

6.  Alpha-2-glycoprotein 1(AZGP1) regulates biological behaviors of LoVo cells by down-regulating mTOR signaling pathway and endogenous fatty acid synthesis.

Authors:  Ligong Chang; Xiaoqiang Tian; Yinghui Lu; Min Jia; Peng Wu; Peilin Huang
Journal:  PLoS One       Date:  2014-06-11       Impact factor: 3.240

7.  Human Epidermal Growth Factor Receptor Expression in Colorectal Cancer and Its Relationship with Clinicopathological Characteristics.

Authors:  Zhila Torabizadeh; Anahita Nosrati; Shadi Tahvildari
Journal:  Middle East J Dig Dis       Date:  2016-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.